Pertagen

Pertagen is a recombinant monovalent acellular pertussis (aP) vaccine developed by BioNet-Asia in collaboration with Mahidol University. It is specifically designed for active immunization against *Bordetella pertussis* in individuals aged 11 years and older. Unlike traditional acellular vaccines that rely on chemical detoxification (e.g., using formaldehyde), Pertagen contains a genetically inactivated pertussis toxin (PTgen) and filamentous hemagglutinin (FHA). This genetic inactivation preserves the natural conformational epitopes of the toxin, which is intended to enhance the induction of protective neutralizing antibodies. Licensed in Thailand in 2016, Pertagen was the first recombinant acellular pertussis vaccine to reach the market. It is currently being evaluated in Phase IV studies to assess long-term antibody persistence and the efficacy of decennial booster doses in adults.

Brand names

Pertagen

Other names

recombinant acellular pertussis vaccineaP vaccinemonovalent pertussis vaccine